Omeprazol Cinfa (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Cinfa, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Omeprazol Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazol Cinfa is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions: - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces the risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with this rare neuroendocrine tumor. - Helicobacter pylori eradication regimens (as part of combination therapy): enhances eradication rates by suppressing acid. - NSA‑induced gastropathy prophylaxis: lowers the risk of ulcer formation in patients requiring long‑term NSAID therapy.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually transient. - Nausea or abdominal discomfort: occasional. - Flatulence: mild bloating. - Constipation: infrequent. - Dry mouth: occasional.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): requires immediate medical attention. - Clostridioides difficile‑associated colitis: may present with watery diarrhea. - Low magnesium levels (hypomagnesemia): can cause muscle cramps or cardiac arrhythmia. - Bone fractures (hip, wrist, spine): reported with long‑term use. - Acute interstitial nephritis: renal inflammation requiring evaluation. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare severe skin reactions.

Omeprazole should be used with consideration of patient‑specific factors and proper storage.

- Assess renal and hepatic function: dose adjustment may be needed in severe impairment. - Review concomitant medications: potential for altered absorption of drugs that require an acidic environment. - Use the lowest effective dose: limit duration to the shortest period necessary for symptom control. - Monitor long‑term users: watch for signs of vitamin B12 deficiency, hypomagnesemia, and bone density loss. - Avoid abrupt discontinuation: taper if therapy exceeds several months to reduce rebound acid hypersecretion. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir and other protease inhibitors: markedly decreased antiviral exposure. - Methotrexate (high dose): increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, requiring more frequent monitoring. - Digoxin: may increase serum levels, especially in the elderly. - Diazepam and other benzodiazepines: enhanced sedative effect. - Iron salts and certain antifungals (e.g., ketoconazole): reduced absorption; separate dosing by at least 2 hours.